Actinium Pharmaceuticals, Inc. (ATNM) Financial Ratios
20 years of historical data (2006–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: 31.06
30Y Low31.1·High31.1
P/B Ratio
↑
4.10
↑+30% vs avg
5yr avg: 3.17
30Y Low1.2·High5.8
ROE
↓
-167.0%
↑-83% vs avg
5yr avg: -91.3%
30Y Low-303%·High-37%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ATNM Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Actinium Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $32M | $42M | $38M | $135M | $257M | $124M | $95M | $32M | $41M | $44M | $42M |
| Enterprise Value | $-13987756 | $-3877588 | $-33442800 | $61M | $151M | $46M | $32M | $25M | $28M | $27M | $22M |
| P/E Ratio → | -0.94 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 359.07 | 471.40 | — | 1668.50 | 249.62 | 108.05 | — | — | — | — | — |
| P/B Ratio | 4.10 | 5.42 | 1.16 | 3.72 | 3.87 | 1.68 | 1.54 | 5.76 | 4.66 | 3.24 | 2.35 |
| P/FCF | — | — | — | — | 31.06 | — | — | — | — | — | — |
| P/OCF | — | — | — | — | 29.74 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ATNM EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -43.08 | — | 747.95 | 146.39 | 40.29 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | 18.21 | — | — | — | — | — | — |
ATNM Profitability
Margins and return-on-capital ratios measuring operating efficiency
Actinium Pharmaceuticals, Inc. earns an operating margin of -40274.4%. Operating margins have expanded from -64098.8% to -40274.4% over the past 3 years, signaling improving operational efficiency. A negative ROE of -167.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | — | 100.0% | 100.0% | 54.2% | — | — | — | — | — |
| Operating Margin | -40274.4% | -40274.4% | — | -64098.8% | -3311.1% | -2182.2% | — | — | — | — | — |
| Net Profit Margin | -37652.2% | -37652.2% | — | -60269.1% | -3205.5% | -2165.6% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -167.0% | -167.0% | -110.6% | -94.9% | -47.2% | -36.7% | -66.3% | -302.9% | -210.4% | -167.9% | -121.7% |
| ROA | -52.7% | -52.7% | -48.3% | -49.9% | -33.9% | -33.8% | -56.9% | -164.9% | -142.4% | -130.2% | -99.0% |
| ROIC | — | — | — | — | — | — | — | — | — | — | — |
| ROCE | -64.4% | -64.4% | -59.5% | -58.8% | -38.5% | -36.9% | -65.9% | -291.3% | -211.8% | -169.9% | -134.3% |
ATNM Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $48M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.22 | 0.22 | 0.05 | 0.06 | 0.04 | 0.00 | 0.01 | 0.25 | 0.03 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -5.91 | -2.18 | -2.05 | -1.60 | -1.05 | -1.03 | -1.39 | -1.52 | -1.27 | -1.14 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | -12.84 | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | -137.44 | -4955.99 | -5361.89 |
Net cash position: cash ($48M) exceeds total debt ($2M)
ATNM Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Actinium Pharmaceuticals, Inc.'s current ratio of 6.20x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 9.21x to 6.20x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.20 | 6.20 | 9.14 | 9.21 | 10.44 | 11.66 | 13.62 | 1.89 | 2.36 | 3.82 | 4.95 |
| Quick Ratio | 6.20 | 6.20 | 9.14 | 9.21 | 10.44 | 11.66 | 13.62 | 1.89 | 2.36 | 3.82 | 4.95 |
| Cash Ratio | 6.02 | 6.02 | 8.95 | 9.03 | 10.25 | 11.38 | 13.34 | 1.73 | 2.26 | 3.73 | 4.54 |
| Asset Turnover | — | 0.00 | — | 0.00 | 0.01 | 0.01 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
ATNM Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Actinium Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | 0.0% | 0.0% | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | 3.2% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $31M | $30M | $27M | $24M | $21M | $12M | $5M | $4M | $2M | $2M |
Peer Comparison
Compare ATNM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ATNMYou | $32M | -0.9 | — | — | 100.0% | -40274.4% | -167.0% | — | — |
 RNAC | $283M | -1.9 | — | — | 100.0% | -3099.9% | — | — | — |
 RAIN | $17M | -1.7 | — | — | — | — | — | — | — |
 PHAT | $864M | -3.6 | — | — | 87.1% | -91.4% | — | — | — |
 NVX | $114M | -0.9 | — | — | 69.8% | -880.0% | -46.5% | -25.6% | — |
 RNW | $2B | 20.1 | 10.3 | — | 58.5% | 43.4% | 8.0% | 5.4% | 8.6 |
 IOVA | $1B | -3.6 | — | — | 97.2% | -153.1% | -55.5% | -48.9% | — |
 MGNX | $263M | -3.5 | — | — | 71.1% | -48.7% | -86.9% | -144.1% | — |
 NVO | $192B | 12.2 | 9.1 | 43.2 | 81.0% | 41.3% | 60.7% | 36.2% | 0.9 |
 BMY | $110B | 15.7 | 8.9 | 8.6 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 NVS | $281B | 20.5 | 13.7 | 15.9 | 75.0% | 31.2% | 31.0% | 18.8% | 1.7 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 20 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
ATNM — Frequently Asked Questions
Quick answers to the most common questions about buying ATNM stock.
What is Actinium Pharmaceuticals, Inc.'s P/E ratio?
Actinium Pharmaceuticals, Inc.'s current P/E ratio is -0.9x. This places it at the 50th percentile of its historical range.
What is Actinium Pharmaceuticals, Inc.'s ROE?
Actinium Pharmaceuticals, Inc.'s return on equity (ROE) is -167.0%. The historical average is -139.6%.
Is ATNM stock overvalued?
Based on historical data, Actinium Pharmaceuticals, Inc. is trading at a P/E of -0.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Actinium Pharmaceuticals, Inc.'s profit margins?
Actinium Pharmaceuticals, Inc. has 100.0% gross margin and -40274.4% operating margin.